Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective

Asia-Pacific Journal of Clinical Oncology

Volumn 8, Issue 1, 2012, Pages 53-61

  Thongprasert, Sumitra ^a   Tinmanee, Sirana ^c   Permsuwan, Unchalee ^b  

^a Maharaj Nakorn Chiang Mai Hospital   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Cost effectiveness analysis; Gefitinib; Non small cell lung cancer

Indexed keywords

DOCETAXEL; ERLOTINIB; GEFITINIB; PEMETREXED;

ADVANCED CANCER; ARTICLE; BUDGET; COST CONTROL; COST UTILITY ANALYSIS; DRUG COST; HEALTH CARE COST; LUNG NON SMALL CELL CANCER; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; THAILAND;

EID: 84857528545     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2012.01528.x     Document Type: Article

References (25)

1. World Health Organization. Cancer. [updated October 2011, cited 23 January 2012.] Available from URL: .
2. Wibulpolprasert S. Thailand health profile report 2005-2007. [Cited 11 Oct 2009.] Available from URL: .
3. Vatanasapt V, Sriamporn S, Vatanasapt P. Cancer control in Thailand. Jpn J Clin Oncol 2002; 32: S82-91.
4. De Petris L, Crino L, Scagliotti GV etal. Treatment of advanced non-small cell lung cancer. Ann Oncol 2006; 17 (Suppl. 2): ii36-41.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T etal. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32.
6. Lee JH, Yu CJ, Chen KY etal. Pemetrexed for heavily pretreated patients with advanced non-small cell lung cancer. J Formos Med Assoc 2010; 109: 338-44.
7. Fuld AD, Dragnev KH, Rigas JR. Pemetrexed in advanced non-small-cell lung cancer. Expert Opin Pharmacother 2010; 11: 1387-402.
8. Hanna N, Shepherd FA, Fossella FV etal. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-97.
9. Kim ES, Hirsh V, Mok T etal. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-18.
10. Permsuwan U, Guntawongwan K, Bhuuhawongsa P. Handling time in economic evaluation studies. (in Thai) In: Chaikledkaew U, Teerawatananon Y, Kongpittayachai S etal. (eds). Thai National Health Technology Assessment Guidelines. Chulalongkorn University Press, Bangkok 2009; 161-85.
11. Drug and Medical Supply Information Center. Prices of drugs and medical supply. [Cited 4 Oct 2010.] Available from URL: .
12. Arthorn Riewpaiboon. Standard cost list for health technology assessment, health technology assessment program (HITAP), Ministry of Public Health, Thailand. Bankok 2010: 33.
13. Ministry of Public Health. Prices of Services of Health Facilities under the Ministry of Public Health. (in Thai) Ministry of Public Health, Nonthaburi 2004.
14. Bank of Thailand. US Dollar and Thai Baht exchange rate. [Cited 7 Apr 2011.] Available from URL: .
15. The National Institute for Health and Clinical Excellence. Details of ERG adjustments to results of Roche submitted economic model. ERG addendum to manufacturers' model, 2007 [Cited 4 Oct 2010.] Available from URL: .
16. Nafees B, Stafford M, Gavriel S etal. Health state utilities for non-small cell lung cancer. Health Qual Life Outcomes 2008; 6: 84.
17. Doyle S. Health state utlity scores in advanced non-small cell lung cancer. Lung Cancer 2008; 62: 374-80.
18. The National Institute for Health and Clinical Excellence. "The risk and cost of febrile neutropenia in patients with non-small cell lung cancer treated with docetaxel". Report by The NICE Decision Support Unit, 2007 [Cited 4 Oct 2010.] Available from URL: .
19. Sub-committee for Development of National List of Essential Drug. Minutes of the 9/2550 Meeting on 20 December 2007. Ministry of Public Health, Nonthaburi 2007.
20. Berger ML, Bingefors K, Hedblom EC etal. Health Care Cost, Quality, and Outcomes. International Society for Pharmacoeconomics and Outcome Research, Lawrenceville, NJ 2003.
21. Martin N. Cancer in Thailand. National Cancer Institute, Full Research Report, Bangkok 1998-2000; 41-4.
22. The Prime Minister's Office. Thailand population projection 1999-2016. [cited 4 Oct 2010.] Available from URL: .
23. de Lima Lopes G Jr, Segel JE, Tan DS, Do YK, Mok T, Finkelstein EA. Cost effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 2011 doi: 10.1002/cncr.26372. [Epub ahead of print].
24. Carlson JJ, Reyes C, Oestreicher N etal. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 2008; 61: 405-15.
25. Horgan AM, Bradbury PA, Amir E etal. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. Ann Oncol 2011; 22: 1805-11.